je.st
news
Tag: patients
Stroke patients show higher recovery in MultiStem therapy studied at UH Case Med Center
2016-02-25 19:01:04| Biotech - Topix.net
Data presented by the biotech company Athersys indicate that stroke patients treated by an adult stem cell therapy called MultiStem did significantly better than others who received a placebo one year after treatment. The results are from a Phase 2 study involving clinical sites in the United States and the United Kingdom, including University Hospitals Case Medical Center.
Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers Disease
2016-01-28 14:00:26| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimers Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the companys investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimers disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA
2016-01-17 19:50:21| Biotech - Topix.net
Novartis announced today that the US Food and Drug Administration has approved Cosentyx for two new indications - the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis . AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine.
Tags: with
treatment
adult
approval
Drug that causes patients to bleed to death was approved under...
2015-12-21 09:57:04| Biotech - Topix.net
Meet Robert Califf . He was recently appointed as Deputy Commissioner for Medical Products and Tobacco at the FDA, by the Obama administration.
Tags: was
under
death
approved
Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
2015-12-19 16:55:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »